CDK2 and breast cancer: They were found to be potent inhibitors of CDK2, CDK5 and CDK7 and had an anti-proliferative activity (IC50 = 4 μM or 10–19 μM for VMY-1-103 or VMY-1-101, respectively) against breast cancer cell lines.